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Strengths and limitations of this study
 ► This review provides an interpretative summary
of the information relevant to the shared decision- 
making process around treatment for older adults
with end- stage kidney failure—a patient group with
increasing numbers worldwide, unclear outcomes
from treatment and for whom clinicians struggle to
provide appropriate advice.
 ► The scoping review format, which collects infor-
mation across a wide range, is relevant as there is
a plethora of issues across multiple domains and
sources to consider in the older adult. This review
summarises information on prognosis, quality of life, 
lived experience of treatment and specific informa-
tion needs in older patients.
 ► In order to preserve focus, this scoping review did
not cover some topics relevant to treatment deci-
sions such as the comparison between dialysis
modalities (especially modified treatments such as
assisted or incremental dialysis) or transplantation,
techniques for presenting information or educating
patients, or the logistic/financial barriers to treat-
ment. We believe several of these topics require ad-
ditional, separate reviews. In addition, our exclusion
of non- English articles neglects research from some
parts of the world.
 ► While this scoping review presents a wide range of
information, it does not grade its quality or study its
delivery to the patient; therefore, the use of this in-
formation in practice is dependent on the individual
clinicians participating in the shared discussions.
AbStrACt
Objectives This review summarises the information 
available for clinicians counselling older patients with 
kidney failure about treatment options, focusing on 
prognosis, quality of life, the lived experiences of treatment 
and the information needs of older adults.
Design We followed the Joanna Briggs Institute 
Methodology for Scoping Reviews. The final report 
conforms to the PRISMA- ScR guidelines.
Data sources PubMed, PsycINFO, CINAHL, Embase, 
Scopus, Web of Science, TRIP and online repositories 
(for dissertations, guidelines and recommendations from 
national renal associations).
Eligibility criteria for inclusion Articles in English 
studying older adults with advanced kidney disease 
(estimated glomerular filtration rate <30 mL/min/1.73 m2); 
published between January 2000 and August 2018. 
Articles not addressing older patients separately or those 
comparing between dialysis modalities were excluded.
Data extraction and synthesis Two independent 
reviewers screened articles for inclusion and grouped 
them by topic as per the objectives above. Quantitative 
data were presented as tables and charts; qualitative 
themes were identified and described.
results 248 articles were included after screening 15 445 
initial results. We summarised prognostic scores and 
compared dialysis and non- dialytic care. We highlighted 
potentially modifiable factors affecting quality of life. 
From reports of the lived experiences, we documented 
the effects of symptoms, of ageing, the feelings of 
disempowerment and the need for adaptation. Exploration 
of information needs suggested that patients want to 
participate in decision- making and need information, in 
simple terms, about survival and non- survival outcomes.
Conclusion When discussing treatment options, validated 
prognostic scores are useful. Older patients with multiple 
comorbidities do not do well with dialysis. The modifiable 
factors contributing to the low quality of life in this cohort 
deserve attention. Older patients suffer a high symptom 
burden and functional deterioration; they have to cope with 
significant life changes and feelings of disempowerment. 
They desire greater involvement and more information about 
illness, symptoms and what to expect with treatment.
IntrODuCtIOn
Physicians are uncomfortable about 
communicating prognosis to seriously ill 
patients.1 2 This is also true for nephrologists 
looking after patients with advanced kidney 
disease.3–7 There is evidence to suggest that 
patients receive insufficient information or 
are unrealistically optimistic about their prog-
nosis.8 9 Patients often wish they had received 
more information prior to commencing dial-
ysis. For instance, they expect their doctors to 
provide them information about prognosis 
even without being prompted to do so.10 11 
Such descriptions highlight the shortcomings 
often encountered when older patients and 
their multiprofessional clinical teams 
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Figure 1  PRISMA flowchart for study inclusion.29
(doctors, renal nurses and other allied health personnel) 
approach the complex decisions about treatment options 
for advanced kidney disease.12
In older patients, the rate of progression of kidney 
disease may not be as rapid as their younger counter-
parts.13 In addition, in older patients who do progress 
to end- stage kidney disease, treatment with dialysis, 
which is the default option, may not always lead to better 
outcomes or improve quality of life.14 15 With this in mind, 
several nephrology centres across the world now offer a 
dedicated programme of conservative management or 
non- dialytic care (ie, holistic patient management that 
does not include dialysis or transplantation; sometimes 
called ‘supportive care’).16–19 The current dilemma, for 
patients and physicians alike, is in deciding which among 
these two options—dialysis or non- dialytic, conservative 
management—is ideal for an individual patient.20
Professional nephrology associations call on the 
community to ensure that decisions regarding dialysis, 
especially in older, sicker adults, be made according 
to the principles of patient- focused, shared decision- 
making.21 22 Open, transparent and complete sharing of 
information, particularly with regards to prognosis and 
quality of life, with dialysis treatment or otherwise, is an 
important part of this process. However, physicians may 
be handicapped by the lack of appropriate information 
regarding outcomes of the various forms of treatment in 
the older population.23 Different prognostic instruments 
that predict renal worsening or survival exist, but while 
some are rigorously developed and validated, others 
may not be accurate or ideally developed.24–27 There is a 
perceived paucity of information on outcomes other than 
survival—such as functional status or quality of life—that 
are important to patients.
While discussing treatment options with older patients 
in the shared decision- making process, professionals have 
to draw on information from different sources (such 
as prognostic studies, reports of quality of life or expe-
riences of patients already on dialysis), spread across 
multiple domains, and not easily available in a consoli-
dated form. Such characteristics are well addressed when 
appraising the literature using the scoping review format, 
which reports on the breadth of information available in 
the area, intending to describe the field and uncover any 
gaps in the literature. We therefore undertook a scoping 
review to identify and summarise information from the 
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Figure 2  Countries of origin and years of publication of included articles.
Table 1 Parameters* included in prognostic studies
Sociodemographic
Age
Gender
Race
Institutionalisation (eg, 
nursing home)
Nephrology care
Mode of treatment (dialysis 
vs non- dialysis care)
Length of renal follow- up
Hospitalisations
Elective vs unplanned start
Related to dialysis
Elective vs unplanned start
Dialysis access
Adequacy
Length of session
Years spent on dialysis
Functional status
Self- rated health
Frailty
Mobility
Falls
Dependence
Activities of daily living
Bedridden status
Body composition
Sarcopenia
Muscle mass and fat
Comorbidities/organ 
function
Number of comorbidities
Diabetes
Hypertension
Dementia
Depression
Visual impairment
Residual urine
Ejection fraction
Biochemical tests
GFR estimated from 
serum creatinine
Rate of fall of GFR
Urine creatinine
Proteinuria
Albumin
Haemoglobin
Calcium
Phosphate
Parathyroid hormone
HbA1c
Cholesterol
C- reactive protein
Testosterone
Plasma pro- ANP
P- cresyl sulfate
Indole sulfate
*Studied individually, or as part of other indices.
GFR, glomerular filtration rate.
published literature that might facilitate the discussions 
about treatment that multiprofessional healthcare team 
members conduct with older people who have advanced 
kidney disease.
MEthODS
The scoping review adhered to the PRISMA- ScR checklist 
for scoping review conduct and reporting, as detailed in 
the online supplementary file 1.28
Objectives and research questions
The objective of this review was to identify and summarise 
the articles providing information relevant to discussions 
of treatment for advanced kidney disease with older 
patients. The specific questions for the review were devel-
oped after a scan of the literature and discussions with 
local clinicians and academics. We explicitly included 
questions that addressed the patient perspective. They 
were further refined by peer review during publication 
of the protocol. The objectives, inclusion criteria and 
methods for this scoping review were specified in a previ-
ously published protocol (see online supplementary file 
2).29
In brief, this scoping review, conducted according to 
the Joanna Briggs Institute Protocol for Scoping Reviews, 
sought to address the following questions in the older 
patient with advanced kidney disease30:
► What are the factors affecting prognosis and survival
(with dialysis treatment or with conservative manage-
ment not including dialysis)?
► Which factors influence the quality of life?
► What information is available regarding the lived
experiences with the various treatment pathways?
► What is known about the information needs of this
population as they consider treatment options?
The study aimed to synthesise information from quan-
titative and qualitative literature, with reference to the 
research questions listed above, so as to
► Provide a coherent summary for clinicians, and
► Explore areas for future research.
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Inclusion criteria
The scoping review included articles that addressed older 
adults with advanced kidney disease and focused specif-
ically on survival/mortality, factors affecting prognosis 
or quality of life, descriptions of the lived experience of 
treatment (on dialysis or conservative management) or 
descriptions of the information needs of older adults. 
These four areas were developed by consensus between 
the authors after considering the areas of relevance to the 
dialysis decision.
In order to capture all relevant data, we included all 
studies where the population studied was described by 
primary researchers using terms such as ‘elderly’, ‘aged’, 
‘geriatric’ or ‘older’, without pre- specifying an age cut- off 
to define the older adult. Advanced kidney disease was 
defined for this review as an estimated glomerular filtra-
tion rate (eGFR) ≤30 mL/min/1.73 m2.
We included articles from the time period of January 
2000 to August 2018. This time period was chosen so as 
to reflect the increasing number of older patients on 
dialysis, the changing attitudes to the treatment of older 
adults in recent years and the establishment of conserva-
tive care without dialysis as a valid treatment option. All 
forms of research, involving both quantitative and quali-
tative methods, and articles that were published in peer- 
reviewed literature as well as the ‘grey’ literature were 
included. The focus was on information that was likely to 
be of value in choosing whether to have dialysis (any type 
of dialysis) or not. Only articles written in English were 
included (as we had limited translation resources).
Exclusion criteria
► Research that did not address older adults (see opera-
tional definition above) as the main population or as
a subpopulation of interest,
► Research that primarily focused on those with an
eGFR >30 mL/min/1.73 m2,
► Research exclusively comparing variations of dialysis
treatment modalities or transplantation with each
other,
► Research describing the effects of interventions other
than dialysis, or
► Research with reports in languages other than English.
Search methodology
Databases searched included PubMed, Embase, PsycINFO, 
CINAHL, EbscoHost, Mednar, Cochrane, TRIP data-
bases and Web of Science for peer- reviewed research, 
and OpenSIGLE, Open Grey, Trove, EThOS,  OATD. org 
and OpenThesis for grey literature. Websites of national 
specialty societies and clinical guideline collections were 
also searched. Searched terms included those relevant for 
older patients, chronic kidney disease, dialysis, conserva-
tive management, prognosis, survival, quality of life, lived 
experiences and information needs. These terms were 
adapted to suit searches in individual databases; examples 
of search terms are provided as online supplementary file 
3.
Initial screening of articles was undertaken by two 
researchers (RR and ST) working independently, using 
the web- based Rayyan QCRI software (Qatar Computer 
Research Institute and Qatar Foundation, Qatar).31 
Charting of included studies and the extraction of rele-
vant information were done using FileMakerPro16 (File-
Maker, California, USA) and Microsoft Excel software 
(Microsoft, Washington, USA). Separate data extraction 
forms and charting sheets were used for the four different 
research questions, as shown in the published protocol.29 
For included articles, the following data were extracted: 
primary author, year of publication, type of research, 
modality of treatment studied, population, focus of 
research and main findings. Forms used for final data 
extraction are provided as online supplementary file 4.
Patient and public involvement
We did not involve patients or members of the public in 
the design or conduct of this scoping review. However, 
two of the research questions for the scoping review 
directly summarised reports of patient experiences and 
information needs.
rESultS
Figure 1 shows the flowchart summarising the selection of 
studies to be included in this scoping review and the reasons 
for exclusion. All 15 445 articles identified in databases 
were imported into the reference management software 
as detailed. Subsequent screening of titles and removal of 
duplicates provided 4776 articles for review with abstracts. 
These articles were divided into groups depending on the 
questions of the survey, and 971 articles used for full- text 
review. Cohen’s kappa for inter- rater agreement between 
the two reviewers during the initial (blinded) screening of 
articles for inclusion was 0.54, suggesting ‘moderate’ agree-
ment.32 Conflicting decisions regarding suitability for inclu-
sion were subsequently resolved by discussion among the 
authors. Finally, 228 articles were included, along with 20 
articles found by hand- searching reference lists of included 
articles, making up 248 articles selected for analysis (see 
online supplementary file 5 for list of included studies). 
This included three theses obtained from screening of the 
grey literature.
The majority of included articles have primary authors 
resident in the English- speaking countries—USA, UK, 
Canada and Australia. Japan, France, Taiwan and Holland 
were the other significant contributors (figure 2). A greater 
proportion of research literature was written in the previous 
5 years (2012–2017); the number of articles on older 
patients with kidney failure showed an increasing trend in 
recent years.
Overall, half the included articles refer to patients on 
haemodialysis exclusively; 18% were studies on patients 
not on dialysis and 5% included all older patients with 
end- stage kidney disease, regardless of treatment choice. 
Peritoneal dialysis patients alone contributed to 8% of 
8 Raj R, et al. BMJ Open 2019;9:e031427. doi:10.1136/bmjopen-2019-031427
Open access 
studies while 17% included patients undergoing both 
peritoneal and haemodialysis.
For purposes of analysis, the included studies were anal-
ysed in groups, according to the research questions for 
the review detailed above (prognosis, quality of life, lived 
experiences and information needs, respectively). The 
following section on results is also presented according 
to these questions.
Characteristics of studies describing prognosis
In all, 112 articles that specifically focused on the prognosis of 
the older patient with advanced kidney failure were included 
in the review. Thirty- four were single- centre studies; 28 
involved patients in multiple centres, while 24 studies, often 
with participant numbers in excess of 1000, were conducted 
as registry- based research. Sixty- six studies (61.8%) were retro-
spective studies (including 20 out of the 24 registry- based 
studies). Studies that only included patients on haemodialysis 
predominated (39 studies).
Content and scope of studies describing prognosis
Mortality/survival was the the most common prognostic 
outcome of interest. Other outcomes were also studied, 
usually in addition to mortality and included quality- of- life 
outcomes, time to renal replacement therapy/end- stage 
kidney disease, hospitalisation and functional or nutritional 
status.
Researchers considered several different variables for inclu-
sion as prognostic markers (table 1). The stated aim in several 
papers was to use easily available, clinical indicators to predict 
prognosis. Most commonly, researchers used a combination 
of variables—clinical, laboratory, demographic or instrument- 
based data to derive prognosis. These variables could be 
grouped into sociodemographic variables (including age, 
nursing home residence), comorbidities, functional status, 
nutritional parameters, aspects of nephrology or dialysis care, 
and biochemical variables (see online supplementary file 6 
for a detailed list).
A common method was to use a combination of vari-
ables in order to predict prognosis. While some studies 
investigated particular combinations of variables in single 
cohorts, others reported inception and validation cohorts, 
presenting the combination of variables as an index or 
prognostic score. Some of these scores were developed 
specifically in patients with renal failure, while others were 
adaptations of prognostic tools used in the general popu-
lation. Table 2 describes such indices that were developed 
exclusively in the older patient or use age as a variable in 
the index to derive prognosis (therefore making them suit-
able for use in the older population).
We identified 12 studies that compared dialysis treat-
ments with conservative management without dialysis. 
Table 3 lists these studies, in chronological order, where 
the older population has been the focus of comparisons 
between dialysis or conservative management.
Characteristics of studies describing effects on quality of life
Eighty studies representing research that evaluated the 
factors influencing the quality of life in older adults on 
dialysis were selected. Of these, 29 were clinical research 
papers, the rest being reviews of related topics or expert 
opinion. Among the 29 articles reporting on original clin-
ical research, 24 used questionnaires or surveys to interro-
gate quality of life. The supplementary materials include a 
list of the commonly used instruments to measure quality of 
life in elders on dialysis.
Content and scope of articles discussing factors influencing 
quality of life
Table 4 lists the factors affecting quality of life, identified 
from analyses of the included articles. They have been 
separated into modifiable and non- modifiable factors for 
convenience.
Age had an impact on quality of life. While physical 
aspects of quality of life in the elders were low, especially 
once on dialysis, other aspects of quality of life such as 
life satisfaction, mental component scores or social well- 
being appeared to be more stable in older than younger 
patients.33 34
Researchers who compared the quality of life outcomes 
in older people between the conservatively managed 
pathway versus the renal replacement pathway reported 
either no major differences between the two or worse 
quality of life with dialysis.35–37
Psychological factors were relevant to quality of life. 
Depression scores, spiritual and emotional well- being and 
even cognitive impairment have been reported to affect 
quality of life.38 39 Functional impairments and frailty, 
diminished exercise and impaired activities of daily living 
all worsened quality of life. Despite diminishing func-
tional status, rates of hospitalisation were not significantly 
different between older and younger patients on dialysis.40 
For patients already on dialysis, several dialysis- related 
factors contributed to quality of life. These included the 
number of years on dialysis, alterations in dialysis regimes 
or the duration of dialysis sessions. Finally, other comor-
bidities such as diabetes, myocardial infarction and stroke 
worsened quality of life.
Characteristics of studies describing lived experience with 
advanced kidney disease
Ninety- four studies that reported on the experiences 
of older adults living with advanced kidney failure were 
included. The majority of articles (74 of 94) detailed orig-
inal clinical research; 23 employed qualitative analysis, 
usually in the form of interview or focus group analysis, 
while 29 used a particular tool or instrument to assess one 
of the aspects of experience. A list of the common instru-
ments used in these studies is provided as online supple-
mentary material, sorted according to the area of analysis.
Content and scope of studies describing lived experience with 
advanced kidney disease
Several studies used scores or indices to study life on dial-
ysis; importance is also given to symptoms, functional and 
cognitive aspects (and, particularly in this age group, to 
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Table 4 Factors affecting quality of life
Potentially modifiable 
factors Non- modifiable factors
Physical status
Functional decline
Frailty
Symptom burden
Unplanned dialysis starts
Depression
Cognitive impairment
Positive social relationships
Sleep disturbances
Impaired nutrition
Cardiovascular health
Dialysis- related factors 
(session length, regimens, 
etc)
Age
Gender
Race
Socioeconomic status 
(some aspects amenable to 
interventions)
Comorbidities (some aspects 
amenable to interventions)
Years spent on dialysis
falls). Discussions of decision- making, survival and ageing 
were also common.
Older patients reported difficulties in getting informa-
tion, feeling disempowered and dominated by the health-
care team and not being part of decisions.41 Patients 
reporting disempowerment were more likely to regret 
the decision to go onto dialysis; this was more common if 
they started dialysis due to family compulsions.42 Patients 
wanted greater involvement in deciding practical aspects 
of dialysis such as dry weight, the time of treatment, 
dietary restrictions or the access to use for dialysis.41
Coping and adaptation to treatment were important 
parts of the narrative. Successful coping was vital.43 
Patients that coped successfully had “a transformed care 
dynamic, positive appraisal and active everyday engage-
ment”.44 Useful coping strategies included letting go, 
overcoming, keeping a sense of humour, looking at the 
good side of things and thinking positively.45 46
The incurability of kidney failure forces patients to rein-
vent themselves, make compromises or adopt beliefs or 
behaviours discordant with medical opinion.47–50 Despite 
these burdens, the majority of patients reported satis-
faction with treatment and improvement of symptoms; 
another study found that the majority of patients reported 
no decision regret or ambivalence about starting dial-
ysis.51 52 It should be noted, however, that patients’ deci-
sions, goals and expectations are not static but change 
with time as different issues emerge.42 53
Patients constantly reflect on themselves in relation to 
others—being a burden, receiving help or having other 
relationships.48 54 Partnership was frequently mentioned, 
whether spousal or with professionals.44 55 Patients 
reported close and supportive relationships with health-
care professionals in some centres; dialysis nurses often 
encouraged patients to be independent and assisted 
with coping.52 Otherwise, elders reflected on the busy 
cultures of units, with infrequent opportunities to speak 
to doctors.56
Several included studies referred to the effects of dial-
ysis on the functional status of older patients, particularly 
in the first 6 months where up to 30% face decline.57–59 
This is even worse in patients living in nursing homes 
where 61% declined in functional status or died within 
the first 3 months; this figure was 87% at 1 year.60 Falls are 
common, particularly soon after dialysis.61
The symptom burden was high, and this was confirmed 
by qualitative studies which provided stories of suffering 
and burden inflicted by dialysis.62 Despite this, scores of 
mental components of quality of life and satisfaction with 
life appear to be stable and equal to or better than that 
for younger patients.33 Other correlates of a good quality 
of life in these studies included living with family rather 
than alone or in a nursing home and having widespread 
social relationships. The social well- being of older dialysis 
patients did not decline significantly with time.63 64 Phys-
ical scores were uniformly lower.60 65 66 There were several 
interactions among these factors, such as those between 
cognition and depression, physical decline and risk of 
falling and insomnia and depression.67 68 Octogenarians 
were frequently hospitalised for infections; while those 
patients who had access to a conservative management 
pathway were less likely to be admitted to hospital, partic-
ularly at the end of life.40 69
Older patients are aware of impending mortality and 
frequently contemplate death.70 These topics are diffi-
cult to talk about.71 The haemodialysis machine is seen 
as a lifeline as it attempts to relieve suffering even though 
dialysis can be seen as a prison, or between life and 
death.41 47 54 Thoughts of stopping dialysis arise often—
increasing age, female gender, dementia and prior cere-
bral vascular disease are risk factors for withdrawal.72 73
Characteristics of studies reporting on information needs of 
the older patient
A total of 32 articles, mostly published in the last 10 years, 
were concerned with information needs of older patients 
with advanced kidney failure. Seventeen articles were 
original research papers, eight were opinion pieces and 
six were reviews (predominantly narrative reviews). Most 
research was in the qualitative realm (12/17 interviews 
and focus groups analysis; 4/17 survey- based analysis).
Content and scope of studies reporting on information needs 
in the older patient
Thematic analysis of the included studies revealed the 
broad themes which are summarised in figure 3. The 
most frequently reported theme related to the need 
for complete information about treatment modalities, 
including non- dialysis pathways. Such information is 
not uniformly provided to patients—discussion about 
conservative care options, for instance, was more likely 
to happen if the particular renal unit had an established 
conservative treatment pathway.8
With a perceived uncertainty regarding kidney disease 
and its treatment requirements, patients desired informa-
tion about kidney disease, progression and the symptoms 
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Figure 3  Information needs—themes elicited.
that may arise, especially with non- dialysis pathways of 
treatment. Even though survival was an important aspect 
of prognosis, of relevance to patients, they often report 
not receiving information regarding this. Clinicians 
are hesitant or unwilling to discuss prognosis for many 
reasons (uncertainty, not wanting to take away hope, 
etc).7 Yet, this is vital information which could affect the 
choices patients make about therapy. Fine and colleagues, 
in two separate questionnaire- based studies on pre- 
dialysis populations, showed that patients expect doctors 
to give them prognostic information even without being 
prompted.10 11
Mortality, and thoughts about dying, were very 
common, especially in those considering conservative 
treatment or discontinuation of dialysis. Some patients 
were reticent to engage with the topic of discontinuation 
and death because they found themselves overwhelmed, 
and continued dialysis even without making a deliberate 
choice to do so—they did not want to think about other 
options since they knew that death was certain without 
dialysis.74 The frequent discussion of mortality and consid-
eration of future care by older patients suggest that they 
will be amenable to advance care planning discussions.
Information needs and dialysis decisions are a fluid 
process, subject to change for most patients.75 With appar-
ently limited choices, the alternative to dialysis appeared 
to be death.76 Patients welcomed the opportunity to 
participate in shared decision- making but regretted the 
‘pressure’ they felt from the clinical team for a decision.77 
They sought information on the outcomes if they did not 
have dialysis or withdrew from treatment.74 In general, 
they requested information pertinent to the older patient 
and reflective of patient- centred values and consider-
ations.78 Patients had their own estimates about the 
importance of quality of life or survival on dialysis rather 
than the perceived benefits of treatment.78–80 As expected, 
patients had different preferred learning styles—for 
instance, some preferred visual aids or written informa-
tion rather than verbal. It was important that informa-
tion be presented in small chunks, in simple rather than 
complex terms and avoiding medical jargon.81
Several practical issues were important to patients. 
These included information on the need for lifestyle, diet 
or fluid intake changes, travel, hospital visits, anticipated 
support needs and availability of support services in the 
community.82
DISCuSSIOn
Older patients with kidney failure turn to their clini-
cians—nephrologists, renal nurses, educators and other 
allied health staff—to discuss their choices of treat-
ment. This scoping review attempted to summarise the 
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published information that is available for use by clini-
cians for these discussions.
An important consideration is that of prognosis with 
treatment. The majority of articles addressing prognosis 
focused on mortality as an outcome. The risks of further 
progression of renal impairment and development of 
end- stage kidney disease are also relevant to prognosis. 
Table 2 lists multiple validated prognostic indices created 
from combining multiple predictors to estimate either 
mortality or risk of progression to end- stage kidney 
disease in older patients. Use of these indices have 
been recommended as an important part of the shared 
decision- making process.22 83 84
The studies summarised in table 3, contrasting dialysis 
care with non- dialysis conservative management, are a 
reminder that specific consideration ought to be given to 
discussions of prognosis since this information could influ-
ence treatment choice. Advancing age has its own prog-
nostic import which needs to be considered separately 
from other factors.12 Older patients, especially those with 
multiple comorbidities, may not derive the same survival 
benefit from being on dialysis as their younger counter-
parts.69 85 86 We recommend the use of tools and models 
developed specifically in older individuals to estimate the 
risks of mortality and the risks of progressing to end- stage 
kidney disease since there are practical implications in 
this age group. For instance, patients with a high risk of 
mortality and a low risk of progression to end- stage kidney 
disease may be better suited to a non- dialysis, conservative 
treatment pathway.84
When elders discuss treatments such as dialysis, they 
face the prospect of significant changes to their life-
style, and therefore there is often a consideration of the 
resultant quality of life (often rated equally important as 
‘quantity’, or longevity). A conservative pathway of care, 
especially if this aligns well with patients’ values, could 
potentially offer better or equal quality- of- life experience 
when compared with dialysis.35 37 87 Other factors merit 
consideration—such as the reduced odds of hospitalisa-
tion on a conservative pathway or the greater likelihood 
that with this pathway, patients were more likely to die in 
a place of their choice or receive palliative care before 
their death.15 35 36 69 88–90 It is worthwhile remembering, 
however, that within the literature, conservative manage-
ment has mostly been compared with routine dialysis 
modalities such as thrice- weekly in- centre haemodialysis. 
Dialysis treatment can be potentially modified to suit the 
needs of older, frailer individuals—such as by the provi-
sion of assisted peritoneal dialysis or reduced frequency 
of haemodialysis sessions. In a recent paper by Iyasere et 
al, it was shown that when patients were provided with 
assistance in performing peritoneal dialysis at home, 
they achieved quality- of- life scores that were better than 
a contemporaneous cohort of conservatively managed 
patients.91 The comparisons between particular modali-
ties of treatment become relevant once the patient makes 
the choice to have dialysis—however, they were not within 
the scope of this review. It must be acknowledged that 
the local availability of treatments tailored to the older 
patient may influence treatment choice. If such modi-
fied treatments can be offered, then this information, 
including the potential benefits and compromises, ought 
to be presented to patients.
There is a paucity of original research on the quality 
of life and the (potentially modifiable) factors that affect 
quality of life, as also evidenced by a 2017 systematic 
review.92 Included studies (29 detailing clinical research) 
suggests that age, gender, physical status, comorbidities, 
cognition and psychological variables such as depression 
affected quality- of- life outcomes in older patients.82 84 87 91 
Our review identified a few potentially modifiable factors 
that could improve quality of life in elders considering 
dialysis. As shown in table 4, some of these factors, such as 
depression, sleep disturbances or poor nutrition, may be 
amenable to intervention in the pre- dialysis stage itself. 
Brown suggests that engaging patients in discussion, 
emphasising lifestyle effects of treatment, considering 
benefits of all interventions—even renal clinic visits—
are additional measures to improve quality of life in 
elders with advanced chronic kidney disease.82 If specific 
measures can be instituted to improve the quality- of- life 
experiences of patients in various pathways, the differ-
ences in patient- reported experiences may be much less 
significant—this is a developing area of clinical practice 
and research.91 93 94
We anticipated that the reports of the lived experi-
ence of previous older patients on dialysis would offer 
valuable insights for those now considering options. Our 
review suggests that while some patients were able to cope 
successfully and ‘reinvent themselves’ in their new lives, 
others described negative outcomes.59 The lived experi-
ence of such patients is dominated by disempowerment, 
lack of knowledge, cognitive impairment, depression, 
difficulties with strict regulations regarding diet, fluid 
and dialysis timings, and finally, functional decline, which 
called into question their relationships with family and 
made them feel a burden to others. Such descriptions 
should prompt clinicians to ensure that older patients 
receive appropriate information about potential life-
style changes prior to starting—this will also mitigate the 
reports of regret at having started dialysis.51 95 96
Patients’ relationships—personal and professional—
play an important role. Multiple social connections and 
close family relationships appear to improve the experi-
ence of dialysis. Healthcare professionals, as expected, 
play important roles in these patients’ lives, which extends 
beyond the initial provision of information for discussion. 
The reports of functional and cognitive decline suggest 
that clinicians should inform potential patients of these 
risks and also periodically measure physical status, func-
tional impairment and cognitive status so that appropriate 
interventions can be planned early.93 97 Qualitative studies 
in this population frequently involve discussions of death 
and mortality, suggesting the importance of discussions 
regarding end- of- life care or advance care directives early 
in the patient course.
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Table 5 Implications for practice
Domains to consider Practical steps Expected benefit in older adults
Making information easy to grasp for 
the older person
Specifically, in older individuals, 
consider how information is provided: 
avoid medical jargon, make allowances 
for cognitive impairment and depression
Promotes health awareness
Strengthens decision- making
Mitigates regret after starting treatment
Involvement of carers/family/friends Proactively identify relevant carers 
especially in frail, dependent elders and 
include them in discussions or when 
planning support
Promotes carer involvement which is 
important to older patients
Mitigates carer burden
Risk of disease progression to end- 
stage kidney disease
Use prognostic indices developed in 
the older population to provide realistic 
estimates of disease progression (see 
table 2)
Identifies patients less likely to progress and 
more suited for supportive measures at that 
particular time
Survival with end- stage kidney disease Use prognostic indices developed in 
the older population to provide realistic 
estimates of survival (see table 2)
Fosters realistic expectations of survival 
benefit
Quality- of- life outcomes Counsel older patients regarding 
possible adverse quality of life with 
treatment, including risk of physical 
deterioration
Explore patients’ expectations from 
treatment and check alignment with 
patients’ values
Promotes the choice of therapy appropriate 
to patients’ values/expectations for life
Fosters realistic expectations
Mitigates regret after starting treatment
Lessons from the experiences of other 
older people
Counsel patients regarding lifestyle 
changes; functional worsening; impact 
on daily life, relationships; persistent 
symptom burden; time commitments; 
need for coping strategies
Finally, we surveyed the literature on patients’ infor-
mation needs. Patients are interested in their prognosis 
(survival, eventual outcome) with and without dialysis 
treatment.4 However, decision- making for patients, carers 
and their healthcare professionals does not rely merely 
on survival statistics.82 There is specific interest in the 
impact of dialysis on personal outcomes such as quality 
of life.10 11 76 80 95 98 Older patients already on dialysis tell 
us that they would have liked more practical knowledge 
about what is actually involved in having dialysis, as well 
as the effects of dialysis on daily life. Matters relevant to 
older patients ought to be presented in a non- technical, 
jargon- free manner, with patient participation, and giving 
them ‘more rather than less’. Our review did not address 
the methods of provision of information.
The information needs of patients summarised above 
are of central importance in discussions of treatment. 
Although these included articles capture the patient 
perspective, it would be beneficial for future researchers 
to seek patient and public involvement even during the 
initial design of questions for a review. Such early involve-
ment could potentially highlight more gaps in the litera-
ture that addresses patient needs.
Practical implications
Older patients are a unique group and clinicians 
preparing to counsel them about treatment choices ought 
to prepare deliberately. Table 5 lists a few practical steps 
for the clinical team to consider based on the domains 
uncovered in our scoping review. The primary aim of this 
discussion is to help patients make appropriate choices, 
with realistic expectations of benefits from treatment and 
a good understanding of the changes in lifestyle occa-
sioned by the treatment.
It is worthwhile to consider how the information from 
this scoping review may be used within recommended 
frameworks for communication and decision- making 
in this patient group. Schell and Cohen suggested the 
SPIRES framework (the acronym SPIRES standing for 
set- up, perceptions and perspectives, invitation, recom-
mendation, empathise, summarise and strategise) to 
help patients weigh up the benefits and risks of dialysis.99 
Similarly, Rosansky and colleagues suggested a frame-
work incorporating clinical and patient considerations 
in arriving at a shared decision.100 Figure 4 suggests how 
available information as summarised in this scoping 
review can be used to guide decisions as these frameworks 
are applied.
In this review, we did not address how this information 
ought to be presented to patients. This is a crucial area 
of research, as there needs to be enquiry into the appro-
priate method of educating older patients as opposed to 
younger cohorts. Subsequently, the effectiveness of these 
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Figure 4 Using available information in a framework for decision- making. Adapted from Schell and Cohen99 and Rosansky et 
al.100 Grey text boxes: information available to guide decisions. Bold arrows: suggested steps in the frameworks. Light arrows: 
influences.
box 1 Areas for future research
1. Prediction of outcomes other than survival (eg, quality of life, func-
tional decline).
2. Factors influencing quality of life in older patients (and the effects of 
modifying these factors).
3. Modifications of treatment to support older individuals (assisted
peritoneal dialysis, incremental dialysis, etc) and their effects on
patient choices and outcomes.
4. Improving the communication of information, and monitoring deliv-
ery and understanding.
5. Studies of the effectiveness of the shared decision- making process
in older patients with kidney disease.
6. Interventions to promote carer education and support.
interventions and this shared decision- making process 
need to be studied. Patient- reported outcome measures 
such as quality of life, satisfaction with care or absence 
of decisional conflict may reflect on the success of the 
process.101–103 Other indicators may include indirect 
evidence such as the proportion of patients withdrawing 
from treatment pathways after initial selection or starting 
treatment. These and other areas for future research are 
highlighted in box 1 below.
COnCluSIOn
Not all older patients progress to end- stage kidney failure, 
and clinicians can use scores that predict the risk of this 
progression, so that discussions and plans are conducted 
appropriately to the patient’s expected course. For those 
older patients who reach end- stage kidney failure, length 
of survival is an important consideration when comparing 
dialysis treatment to conservative care, particularly if 
there are multiple comorbidities. Clinicians now have 
several validated indices to help with prognostication. 
However, as evident from this scoping review, longevity 
or survival are not the only factors patients and fami-
lies take into account—there are other expectations of 
treatment, such as the anticipated quality of life or func-
tional status. Some factors influencing quality of life are 
modifiable. The study of lived experiences of dialysis in 
older people informs us of the requirements for patients 
to adapt to their new realities, and the problems from 
functional deterioration, dependency and persistent 
symptoms. Patients should be forewarned about these 
potential outcomes and preventive measures considered. 
All information ought to be presented in a manner that 
the older patient can easily understand, retain and apply. 
Further research is needed into quality- of- life outcomes 
in older individuals, methods of efficient communication 
of information and assessment of the success of shared 
decision- making.
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